2024
Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial
Ramakrishnan D, Brüningk S, von Reppert M, Memon F, Maleki N, Aneja S, Kazerooni A, Nabavizadeh A, Lin M, Bousabarah K, Molinaro A, Nicolaides T, Prados M, Mueller S, Aboian M. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial. American Journal Of Neuroradiology 2024, 45: 475-482. PMID: 38453411, PMCID: PMC11288571, DOI: 10.3174/ajnr.a8189.Peer-Reviewed Original ResearchArea under the curvePediatric gliomasBT-RADSResponse assessmentPartial responseClinical trialsVolumetric analysisReceiver operating characteristic analysisBrain Tumor ReportingReceiver operating characteristic curveModel estimation timeOperating characteristic analysisEvaluate treatment efficacyStable diseasePartial respondersManual volumetric segmentationNo significant differenceSolid tumorsProspective studyTumor ReportingClinical decision-makingTreatment efficacyGliomaSignificant differenceCharacteristic curve
2023
Intraprocedural C‐arm dual‐phase cone‐beam enhancement patterns correlate with tumor absorbed dose after radioembolization
Bastiaannet R, Lin M, Frey E, de Jong H. Intraprocedural C‐arm dual‐phase cone‐beam enhancement patterns correlate with tumor absorbed dose after radioembolization. Medical Physics 2023, 51: 3045-3052. PMID: 38064591, PMCID: PMC10994751, DOI: 10.1002/mp.16882.Peer-Reviewed Original ResearchContrast-enhanced cone-beam CTHepatocellular carcinomaPET/CT scansNon-tumor liver tissuesPersonalized treatment planningIntra-procedural imagingBlood flow patternsPretreatment tumorRetrospective studyLimits of agreementTumor responseBland-Altman analysisClinical trialsTumor doseCT scanEnhancement patternHepatic vasculatureHCC tumorsCatheter positionTumor tissueLiver tissueTumorsHepatic radioembolizationPatientsDose
2022
LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOC clinical Neuro-oncology trials
von Reppert M, Lin M, Bousabarah K, Familiar A, Velasco R, Waanders A, Vossough A, Haddock A, Nicolaides T, Swanson K, Kazerooni A, Kline C, Nabavizadeh A, Haas-Kogan D, Prados M, Rubin J, Mueller S, Aboian M. LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOC clinical Neuro-oncology trials. Neuro-Oncology 2022, 24: i100-i100. PMCID: PMC9165161, DOI: 10.1093/neuonc/noac079.364.Peer-Reviewed Original ResearchPediatric low-grade gliomasClinical trialsLow-grade gliomasRANO criteriaResponse assessmentNeuro-oncology trialsSingle-agent everolimusTreatment response analysisCentral imaging reviewInter-reader agreementClinical outcomesTumor sizeImaging reviewCystic componentTreatment responseTumor volumeTrue tumor volumeNovel treatmentsVolumetric assessmentTrial outcomesVolumetric measuresEntire tumorOverall discordanceNeuroradiology practiceTrials
2021
Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinoma
2014
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clinical Cancer Research 2014, 20: 6406-6417. PMID: 25326230, PMCID: PMC4300523, DOI: 10.1158/1078-0432.ccr-14-1271.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaSuit-2 cell lineOrthotopic xenograft mouse modelBioluminescence imagingFavorable toxicity profileSublethal drug concentrationsAnti-invasive effectsXenograft mouse modelPDAC cell linesCell linesXenograft tumor modelHalf maximal inhibitory concentrationStrong anticancer effectsPancreatic cancerClinical trialsDuctal adenocarcinomaMouse modelToxicity profileIC50 profileTherapeutic efficacyMatrigel invasionVivo efficacyBLI signalMatrigel assaysMiaPaCa-2